Should I treat Group B Streptococcus isolated from the urine of a non‑pregnant 55‑year‑old woman with systemic lupus erythematosus and a history of recurrent urinary tract infections?

Do Not Treat GBS Bacteriuria in This Patient

In a non-pregnant 55-year-old woman with lupus and recurrent UTIs, you should NOT treat Group B Streptococcus isolated from urine if she is asymptomatic. The 2019 IDSA guidelines explicitly recommend against treating asymptomatic bacteriuria (ASB) in non-pregnant adults, as antimicrobial treatment does not improve morbidity or mortality and may actually increase the risk of subsequent symptomatic UTIs 1.

Key Decision Points

Is the Patient Symptomatic?

• If asymptomatic (no dysuria, frequency, urgency, suprapubic pain, fever): Do not treat
• If symptomatic with signs of cystitis or pyelonephritis: Treat appropriately

This distinction is critical because the evidence shows that treating ASB provides no clinical benefit and may cause harm.

Evidence-Based Rationale

Why Not to Treat Asymptomatic GBS Bacteriuria

The IDSA guideline 1 demonstrates that:

• Antimicrobial treatment of ASB does not decrease the frequency of symptomatic infections
• Treatment does not prevent further episodes of ASB
• Microbiologic resolution after treatment is not sustained
• Most importantly: Treatment may actually be protective—one randomized trial showed that antimicrobial therapy for ASB was an independent risk factor (hazard ratio 3.09) for developing symptomatic UTI in women with recurrent UTI history 1

Special Considerations for Lupus

A 2022 cross-sectional study specifically examined lupus nephritis patients 2 and found:

• No statistically significant association between ASB and occurrence of infection (p=1.000)
• No association between ASB and disease activity
• UTI occurred in only 5.3% of patients with ASB versus 5.6% without ASB
• The authors concluded that treatment of ASB contributes to inappropriate antimicrobial use and promotes resistance

Even in immunocompromised lupus patients receiving cyclophosphamide, ASB did not predict subsequent infection 2.

Important Caveats

When Lupus Might Matter

While lupus itself doesn't change the recommendation for ASB, be vigilant for:

• Active lupus nephritis with high disease activity (SLEDAI score)
• Current cyclophosphamide therapy (identified as a risk factor for symptomatic UTI) 3
• Diabetes mellitus as a comorbidity (increases GBS infection risk) 4

In these scenarios, maintain a lower threshold for treating symptomatic infections, but still do not treat ASB.

The "Recurrent UTI" History

The patient's history of recurrent UTIs might tempt you to treat, but the evidence suggests the opposite. The IDSA guideline 1 specifically studied women with recurrent UTI history and found that treating their ASB tripled their risk of developing symptomatic UTI. The hypothesis is that ASB may provide colonization resistance against more virulent pathogens.

Clinical Pitfalls to Avoid

1. Don't confuse colonization with infection: GBS in urine at >10^5 CFU/mL without symptoms is colonization, not infection
2. Don't extrapolate pregnancy data: GBS bacteriuria requires treatment in pregnancy due to risks of pyelonephritis and preterm birth 1, but this does not apply to non-pregnant adults
3. Don't assume immunosuppression changes the recommendation: Even in lupus patients on immunosuppression, ASB treatment showed no benefit 2
4. Avoid contributing to resistance: Unnecessary treatment of ASB is a major driver of antimicrobial resistance 2

When to Reassess

Monitor for development of symptoms and treat promptly if they occur. GBS remains susceptible to penicillin 4, though fluoroquinolone resistance is increasing (12.8% in one study) 4. If symptomatic infection develops, penicillin or amoxicillin would be first-line choices.